Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Effect of Chemotherapy on the Mutation Frequency of Ovarian Cancer Cells at the HPRT Locus

CICEK GERCEL-TAYLOR, JEREMY J. SCOBEE and DOUGLAS D. TAYLOR
Anticancer Research May 2005, 25 (3B) 2113-2117;
CICEK GERCEL-TAYLOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cgtayl01{at}gwise.louisville.edu
JEREMY J. SCOBEE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOUGLAS D. TAYLOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Objective: Resistance to chemotherapy in ovarian cancers is a difficult problem. Our objective was to demonstrate the effect of chemotherapeutic agents, used in the treatment of ovarian cancer, on the mutation frequency of ovarian cancer cells at the HPRT locus. Materials and Methods: Single cell clones were isolated from a recently established ovarian cancer cell line. The cells were then exposed to sublethal doses of cisplatin, paclitaxel or topotecan. After recovering from the cytotoxic effect of these agents, mutation frequencies of the treated and control cells were determined in 6-thioguanine. Results: Recovery from chemotherapeutic agents was variable among clones. Cisplatin had 5/8 clones showing an enhancement in the induced mutation frequency. Paclitaxel had only 1/7 clones showing a positive increase in the induced mutation frequency, the parent line. Finally topotecan had 3/8 colonies showing an accelerated induced mutation frequency. A total of 9/23 clones with an accelerated induced mutation frequency were identified following various chemotherapeutic agents. Conclusion: We demonstrated that, in a limited number of colonies from an ovarian cancer, there was an ability to increase the mutation frequency at the HPRT locus after exposure to common chemotheraputics used in the treatment of this disease. This induction of more mutations by chemotherapy may help explain the developing chemoresistance of this disease during or following treatment.

  • Ovarian cancer
  • chemotherapy
  • cisplatin
  • taxol
  • topotecan

Footnotes

  • Received May 19, 2004.
  • Accepted March 23, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 25, Issue 3B
1 May 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Chemotherapy on the Mutation Frequency of Ovarian Cancer Cells at the HPRT Locus
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
14 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Effect of Chemotherapy on the Mutation Frequency of Ovarian Cancer Cells at the HPRT Locus
CICEK GERCEL-TAYLOR, JEREMY J. SCOBEE, DOUGLAS D. TAYLOR
Anticancer Research May 2005, 25 (3B) 2113-2117;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Effect of Chemotherapy on the Mutation Frequency of Ovarian Cancer Cells at the HPRT Locus
CICEK GERCEL-TAYLOR, JEREMY J. SCOBEE, DOUGLAS D. TAYLOR
Anticancer Research May 2005, 25 (3B) 2113-2117;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Dysregulation of Purine Nucleotide Biosynthesis Pathways Modulates Cisplatin Cytotoxicity in Saccharomyces cerevisiae
  • Google Scholar

More in this TOC Section

  • Coumarin-based Oximes Exert Monoamine Oxidase Inhibitory Activity
  • Selective Inhibition of Protein Kinase D2 Activity Reduces Human Neutrophil Survival
  • POM121 Drives Gastric Cancer Progression via the mTOR/p70S6K Signaling Axis
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire